Since their clinical emergence in the 1980s, monoclonal immunoglobulins (mAbs) have catalyzed paradigm-shifting innovations in medical diagnostics and therapeutics, ultimately emerging as cornerstone biological therapeutics. These homogeneous immunoglobulin populations derived from clonal B-cell lineages exhibit exclusive binding to singular antigenic determinants. Their production leverages hybridoma methodology–a somatic cell hybridization protocol combining antigen-primed antibody-secreting lymphocytes with immortalized myeloma cells to generate perpetual antibody-producing hybridomas. The technology confers distinct advantages, including unparalleled biochemical specificity, enhanced analytical sensitivity, minimized cross-reactivity profiles, and scalable manufacturing economics.